FindTrial
Sign In

AADvac1

BIOLOGICAL7 trials

Sponsors

Axon Neuroscience SE, Paul S. Aisen, Adam Boxer

Conditions

Alzheimer DiseaseAlzheimer's DiseasePSP - Progressive Supranuclear PalsyPreclinical Alzheimer's DiseaseProdromal Alzheimer's DiseaseProgressive Supranuclear Palsy(PSP)

Phase 1

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
CompletedNCT01850238
Axon Neuroscience SEAlzheimer Disease
Start: 2013-05-31End: 2015-03-31Updated: 2015-10-12
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
CompletedNCT02031198
Axon Neuroscience SEAlzheimer's Disease
Start: 2014-01-31End: 2016-12-31Updated: 2017-03-17

Phase 2

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
CompletedNCT02579252
Axon Neuroscience SEAlzheimer's Disease
Start: 2016-03-31End: 2019-06-30Updated: 2019-11-14
Alzheimer's Tau Platform: Master Protocol
Not yet recruitingNCT06957418
Paul S. AisenAlzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Start: 2026-06-30End: 2028-08-31Target: 900Updated: 2026-04-06
Alzheimer's Tau Platform: Regimen A - AADvac1
Not yet recruitingNCT07167966
Paul S. AisenAlzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Start: 2026-06-30End: 2028-08-31Target: 450Updated: 2026-04-06
The Progressive Supranuclear Palsy Clinical Trial Platform
Not yet recruitingNCT07173803
Adam BoxerProgressive Supranuclear Palsy(PSP)
Start: 2026-06-30End: 2030-09-28Target: 440Updated: 2026-04-27
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
Not yet recruitingNCT07217665
Adam BoxerPSP - Progressive Supranuclear Palsy
Start: 2026-06-30End: 2030-09-28Target: 146Updated: 2026-04-27

Related Papers

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
Alzheimer s Research & Therapy2024-11-2311 citations
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial.
2023-12-1428 citations
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease
Alzheimer s Research & Therapy2018-10-24140 citations
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
2016-12-10192 citations
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Alzheimer s Research & Therapy2014-08-01243 citations